Molecular Insight Acquires Novartis’ Onalta
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of the radiolabeled oncologic peptide is firm’s second deal in the past week.
You may also be interested in...
Bayer Schering Licenses Oncology Candidate To Molecular Insight
The Cambridge, Mass. biotech will develop the compound as a radiotherapeutic for malignant melanoma.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.